Aligos Therapeutics (ALGS) Set to Announce Earnings on Wednesday

Aligos Therapeutics (NASDAQ:ALGS) is set to issue its quarterly earnings data after the market closes on Wednesday, November 6th. Analysts expect the company to announce earnings of ($2.15) per share for the quarter.

Aligos Therapeutics (NASDAQ:ALGS) last posted its earnings results on Tuesday, August 6th. The company reported $0.75 earnings per share for the quarter, topping the consensus estimate of ($4.00) by $4.75. Aligos Therapeutics had a negative net margin of 1,100.48% and a negative return on equity of 110.59%. The firm had revenue of $1.06 million during the quarter. During the same quarter in the previous year, the business earned ($10.75) EPS. On average, analysts expect Aligos Therapeutics to post $-8 EPS for the current fiscal year and $-13 EPS for the next fiscal year.

Aligos Therapeutics Trading Up 1.8 %

Aligos Therapeutics stock traded up $0.17 during mid-day trading on Tuesday, hitting $9.65. 33,013 shares of the company traded hands, compared to its average volume of 38,475. Aligos Therapeutics has a one year low of $6.76 and a one year high of $30.00. The stock has a fifty day moving average price of $10.06 and a 200-day moving average price of $12.80.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a “buy” rating and issued a $75.00 price target on shares of Aligos Therapeutics in a research note on Wednesday, October 23rd.

Aligos Therapeutics Company Profile

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).